Task order 75N93022F00001 base award
Active Awarded Last action
- Contract number
- 75N93022F00001
- Awardee
-
Dynport Vaccine Company LLC UEI LXNEGTYDR755
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,028,570
Award facts
- Opportunity
-
- Early Phase Clinical Trial Units (EPCTU) Pre-Solicitation · 75N93020R00023 · Posted Nov 19, 2020
- Contract value 47% obligated
-
- $1,028,570.00 Current, with exercised options
- $2,191,163.00 Potential, with all options
- Completion date 48% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 6 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $219,136 | |
| Exercise an Option | $215,604 | |
| Exercise an Option | $212,105 | |
| Exercise an Option | $208,820 | |
| Original award | $172,905 |
About this award
The National Institute of Allergy and Infectious Diseases awarded Task Order 75N93022F00001 to Dynport Vaccine Company LLC, a General Dynamics subsidiary, on January 21, 2022, with a ceiling value of $2.19 million and a completion date of January 13, 2032. This delivery order operates under the Early Phase Clinical Trial Units IDIQ, a $346 million multiple-award vehicle designed to support Phase I clinical trial services for infectious disease candidates. The contract employs a cost-plus-fixed-fee pricing structure without set-aside designation and will be performed at Dynport's Frederick, Maryland facility.
Dynport Vaccine Company LLC's DVC Segment Division specializes in research, development, manufacturing, and testing services for biopharmaceutical products targeting infectious diseases. The company maintains significant experience conducting preclinical development, clinical trials, diagnostic testing, and vaccine stability evaluations, with past federal awards supporting process development, assay validation, pilot manufacturing, and Phase I trials. In addition to this delivery order, Dynport holds prime contracts including a $30 million Preclinical Services for Biopharmaceutical Product Development IDIQ and a $36 million Diagnostic Pre-Clinical Services Program contract, positioning the firm as a key partner for NIAID's vaccine and therapeutic development initiatives.
Quick answers
Who was awarded contract 75N93022F00001?
75N93022F00001 was awarded to Dynport Vaccine Company LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on January 21, 2022.
How much is contract 75N93022F00001 worth?
The government has obligated $1,028,570 on 75N93022F00001. Its potential value, with all options, is $2,191,163.
Is contract 75N93022F00001 an order under another contract?
Yes. 75N93022F00001 is a delivery order under 75N93022D00016, an indefinite delivery contract, on Early Phase Clinical Trial Units (EPCTU).
Was contract 75N93022F00001 competed?
The extent of competition for 75N93022F00001 was full and open competition. The government received 6 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award